Corteria Pharmaceuticals

The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in financing to help wrap up a Phase III trial for its lead, and sole, clinical asset lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH). The funds will mostly go towards completing the Phase III trial (NCT04849728) for lanifibranor. Preparation for marketing approval filings and drug commercialisation also stand to benefit, as per a 14 October press release. The French biopharma will immediately receive $103.4m of the multi-tranche equity financing, with the remainder coming through future issuance phases. Inventiva also announced a further $30m that has been secured separately in milestone payments via an existing license and collaboration agreement with Chinese pharma company CTTQ. Shares in the Nasdaq-listed company were up 27% at market open on 14 October compared to the market close on 11 October. Inventiva has a market cap of $98.6m. The transaction was led by New Enterprise Associates, BVF Partners LP and Samsara BioCapital, with the participation of additional existing and new investors. Dr. Mark Pruzanski, current chairman of Corteria Pharmaceuticals and biotech Abcuro, will join Iventiva as company chairman. Srinivas Akkaraju, founder of Samsara BioCapital, will serve as a director following the deal. Four additional directors from the other four largest investors will also join the board, with at least two replacing existing directors. See Also: FDA approves Pfizer’s HYMPAVZI to treat haemophilia Cell and gene therapy approvals drive paradigm change in manufacturing Lanifibranor is Inventiva’s only clinical candidate, and the biopharma previously estimated it would need around €250m to finance its activities until Phase III topline results in MASH patients are reached. The study, called NATiV3, is expected to hit this milestone in the second half of 2026. The randomised, double-blind, placebo-controlled trial aims to assess the long-term efficacy and safety of lanifibranor in adults with biopsy-proven non-cirrhotic MASH and F2/F3 stage liver fibrosis. Around 1,000 patients are expected to enrol in the study across 494 study locations, as per a ClinicalTrials.gov entry. The trial is back on track following a halt in recruitment earlier this year due to a possible treatment-related serious adverse event (AE). The MASH treatment space has seen increased interest this year, with Madrigal Pharmaceuticals winning the first US Food and Drug Administration (FDA)-approval in the arena for Rezdiffra (resmetirom). GlobalData estimates the MASH market to reach sales of $25.7bn in 2032 across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan). Lanifibranor is an orally administered small molecule that activates three peroxisome proliferator-activated receptor (PPAR) isoforms. These ligand-activated transcription factors are known to regulate four components of MASH, such as inflammation, fibrosis, steatosis and metabolism.  Inventiva’s pan-PPAR agonist demonstrated positive results in a Phase IIb trial, meeting primary and key secondary endpoints. Inventiva’s CEO Frederic Cren said: “This [financing] reflects the confidence of the participating investors and our partner CTTQ in the value of lanifibranor as a breakthrough therapy for patients suffering from MASH. The total proceeds from the financing will support the MASH programme and subsequent filing for marketing approval, along with preparations for the potential commercialisation of lanifibranor.”

▎药明康德内容团队编辑奥博资本是全球最大的医药领域投资公司之一，其投资覆盖全球生物医疗行业，从初创期企业到大型上市公司都有所覆盖。它已投资并孵化了多家拥有创新平台的生物医药公司。在2023年，奥博资本在生物医药领域的投资活动依然活跃，至少参与了24起创新药领域投资。对奥博资本2023年投资生物医药公司事件（24起投资，23家获投公司）进行分析，发现：1. 奥博资本领投了4家创新药公司的融资，分别为Convergent Therapeutics的A轮融资、Corteria Pharmaceuticals的A轮融资、Garuda Therapeutics的B轮融资及益杰立科的A轮融资。同时，所有创新药投资中有16家公司是继续投资。2. 创新分子疗法为投资关注重点：投资公司中，15家创新药公司研发新分子疗法，其中创新抗体（7家）、核酸药物（3家）及基因疗法（3家）为重中之重。3. 抗肿瘤药物为关注重点，被投资公司中9家布局研发抗肿瘤药物。其中值得关注的公司有精准放射疗法研发公司Convergent Therapeutics及基于人工智能开发精准免疫调节剂公司Odyssey Therapeutics等。4. 3家中国公司获投：获投公司分别为小核酸药物研发公司靖因药业、肌肉骨骼疾病药物研发公司安济盛生物及基因编辑技术研发公司益杰立科。#  ADARx完成2亿美元C轮融资2023年8月9日，ADARx Pharmaceuticals宣布成功完成超额认购的2亿美元C轮融资，所得资金将用于进一步推进ADARx的临床项目，包括ADX-324和ADX-038，以及支持推进用于治疗多种疾病的创新mRNA沉默或RNA编辑候选药物的开发。此次融资由贝恩资本生命科学基金和TCGX共同领投，ADARx的现有投资者礼来亚洲基金（Lilly Asia Ventures）、奥博资本和SR One Capital Management等也参与了本轮投资。2023年1月20日，ADARx Pharmaceuticals也完成了来自Ascenta Capital领投、奥博资本等参与的B1轮融资。ADARx公司位于圣地亚哥，是一家处于临床阶段的生物技术公司，致力于将前沿科学转化为拯救生命的疗法。ADARx正在开发一种不受限于治疗模式的RNA靶向平台，包括用于抑制、降解和编辑寡核苷酸的技术平台，以及新型寡核苷酸递送技术。具体来说，ADARx的专有技术平台包含4大功能模块：RNA编辑，RNA降解和抑制，肝脏递送，以及中枢神经系统递送模块。#   靖因药业完成6000万美元的B轮融资2023年10月16日，靖因药业（Sirius Therapeutics）宣布完成6000万美元的B轮融资，以推进其siRNA新型疗法产品管线的临床开发和新一代核酸分子递送技术的迭代创新。本轮融资由汉康资本领投，康禧全球投资基金参与跟投，原有投资方奥博资本和泓元资本持续追加投资。靖因药业成立于2021年，地址位于上海，聚焦新一代核酸创新疗法在心血管疾病领域的开发，致力成为颠覆慢病防治的领军者。据官网介绍，该公司已经成功搭建具有自主知识产权的RNAi药物研发平台，包括序列设计与筛选、化学修饰与优化、GalNAc偶联递送系统等核心能力，并已开发丰富的第一代心血管领域siRNA候选产品。#   ReCode Therapeutics完成其B轮扩展融资2023年9月19日，ReCode Therapeutics宣布完成其B轮扩展融资，从中额外筹集了5000万美元，使得B轮融资总额达到2.6亿美元。参与此次扩展融资的新投资者包括BLV和Solasta Ventures，现有投资者包括奥博资本、辉瑞风险投资（Pfizer Ventures）、赛诺菲风投（Sanofi Ventures）、安进风险投资（Amgen Ventures）等。ReCode Therapeutics是一家处于临床阶段的基因疗法公司，该公司利用精准递送技术推动下一代mRNA疗法和基因矫正疗法的发展。公司的SORT LNP平台可将基因治疗药物直接高度精确地靶向输送到疾病相关的器官和细胞，从而提高疗效和效力。该公司的主要项目包括RCT1100和RCT2100。这两款疗法是使用SORT LNP递送平台配制的基于mRNA的吸入式疾病调节疗法。ReCode Therapeutics正在扩大其产品管线，开发可治疗其他罕见和常见遗传疾病的潜在疗法，适应症范围包括骨骼肌系统、中枢神经系统、肝脏和传染病。#   Upstream Bio完成2亿美元B轮融资2023年6月8日，Upstream Bio，一家来自美国的免疫疗法研发公司，宣布完成2亿美元B轮融资，该笔资金将用于支持UPB-101的下一阶段临床开发。本轮投资由 Enavate Sciences和Venrock Healthcare Capital Partner领投，奥博资本等投资机构参投。UPB-101旨在阻断胸腺基质淋巴细胞生成素受体（TLSPR），从而抑制TSLP驱动的炎症。TSLP是一种细胞因子，也是哮喘和其他过敏性/炎症性疾病中炎症反应的关键驱动因素。由于TSLP是炎症级联反应的上游靶点，因此有机会在其他下游的疾病相关细胞因子（如IL-4、IL-5、IL-13、IL-17和IgE）产生影响之前从源头上治疗疾病。UPB-101目前处于1b期开发阶段，用于治疗哮喘。此次融资将支持这家公司开发高度差异化的目标产品。#   Terremoto Biosciences完成Ｂ轮融资2023年11月2日，Terremoto Biosciences宣布成功完成了1.75亿美元的Ｂ轮融资轮。这轮投资包括新投资者EcoR1 Capital、Novo Holdings和Cormorant Capital在内的投资者，此外还获得现有投资者奥博资本和Third Rock Ventures的持续支持。Terremoto是一家药物发现和开发公司，致力于利用一种创新的扩展共价技术来开发精确的小分子治疗药物，旨在治疗一系列严重和危及生命的疾病。该公司正在战略性地部署其开创性技术，不仅开发针对既定药物靶标的潜在“best-in-class”疗法，还发现、开发针对高价值靶标的突破性疗法，以治疗那些具未竟医疗需求的疾病。#   ArriVent Biopharma完成超额认购的B轮融资2023年3月27日，ArriVent Biopharma宣布完成超额认购的B轮融资，筹集了1.55亿美元。这些资金将用于支持公司的主要候选药物伏美替尼（furmonertinib）的关键3期试验和针对更多适应症的相关研究，以及支持ArriVent持续扩展其产品管线。这次投资由ofinnova Investments and General Catalyst领投，此外还获得现有投资者奥博资本和礼来亚洲基金等的持续支持。2024年1月27日，ArriVent BioPharma成功完成1.75亿美元的超额认购IPO。ArriVent是一家致力于加速创新生物医药产品开发的公司，其主要候选药物伏美替尼是一种具有高度脑渗透性、靶向EGFR突变的激酶抑制剂。伏美替尼已经于2021年3月在中国获批，用于EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者。ArriVent公司正在探索进一步开发伏美替尼用于携带其他EGFR突变的NSCLC患者，以及其他实体瘤患者。#   Odyssey Therapeutics完成C轮融资12月5日，Odyssey Therapeutics宣布完成1.01亿美元C轮融资，所得资金将用于推进其精准免疫调节剂和肿瘤药物的研发。本轮融资由 Ascenta Capital领投，新老投资者跟投，包括奥博资本、SR One、General Catalys等投资机构。Odyssey Therapeutics成立于2018年，是一家专注于发现、开发和商业化下一代免疫调节剂和肿瘤药物的生物技术公司。2022年1月，Odyssey收购了量子机器学习公司Rahko，为Odyssey的发现平台增加了基于物理的分子模拟、机器学习和计算能力，以实现一流的先导化合物识别和候选药物优化。目前，Odyssey正在构建一个将人工智能和机器学习相结合用于分子设计的发现引擎，一个包含针对多种氨基酸、分子胶和天然产物的专有共价库的化学平台，以及用于新靶点发现的功能基因组学平台。此外，Odyssey正在迅速推进免疫学和肿瘤学项目，专注于那些已被验证但尚无上市的解决方案的靶点。目前的管线包括10个小分子或蛋白质药物项目。#  Iambic Therapeutics完成1亿美元B轮融资 2023年10月3日，Iambic Therapeutics宣布完成1亿美元B轮融资。此次融资由Ascenta Capital和Abingworth共同领投，新投资者包括英伟达（NVIDIA）、Illumina Ventures等。现有投资者也参与其中，包括奥博资本和红杉资本（Sequoia Capital）等。Iambic Therapeutics致力于利用人工智能（AI）药物发现平台开发新疗法。通过将物理学和人工智能相结合，该平台可识别具有差异化药物特征的候选治疗药物。公司现有两种可进入临床的候选药物，高选择性和脑渗透性HER2抑制剂（IAM-H1）和选择性双CDK2/4抑制剂（IAM-C1），可解决细胞周期驱动癌症在治疗方面未满足的需求。此外，公司还创建了NeuralPLexer和OrbNet等方法来驱动其发现平台。据悉，本轮融资将用于推进公司候选药物的临床开发，扩大药物管线，并继续建设其人工智能药物发现平台。#  Triveni Bio宣布完成9200万美元A轮融资 2023年10月26日，Triveni Bio宣布完成9200万美元A轮融资。据悉，本轮融资资金将用于推动Triveni Bio先导抗体项目（TRIV-509）从临床前开发到2a期临床试验的进展，并助力新型抗体的研发。此次融资由Atlas Venture和Cormorant Asset Management共同领投，奥博资本（OrbiMed）和其他投资者参投。Triveni Bio是一家生物技术公司，通过融合人类遗传学、同类最佳抗体设计和精准医学方法，Triveni Bio致力于功能性抗体药物的研发。公司先导抗体项目（TRIV-509）能靶向激肽释放酶5和7（KLK5/7），从而治疗特应性皮炎、哮喘、其他免疫学及炎症（I&I）适应症。#  Convergent Therapeutics完成A轮融资 2023年5月3日，Convergent Therapeutics宣布完成9000万美元A轮融资，本轮融资由奥博资本和RA Capital Management领投。Convergent专注于开发治疗前列腺癌和其他癌症的下一代放射性药物疗法。公司的主要候选产品CONV01-α是一种与锕-225（Ac-225）结合的单克隆抗体，专为与前列腺特异性膜抗原（PSMA）结合而设计。锕-225是一种放射性α粒子发射器。CONV01-α的一个关键功能特性是，一旦与PSMA结合，它就会被内化，将其强大的放射性有效成分直接送入前列腺癌细胞，同时极大限度地降低对周围健康组织的损害。CONV01-α有望成为获批用于前列腺癌治疗的Ac-225放射性抗体。#   Corteria Pharmaceuticals完成A轮融资Corteria Pharmaceuticals宣布完成A轮融资，总额高达6500万欧元（折合约7100万美元）。此次超额认购融资由新投资者Jeito Capital和奥博资本共同领投，现有投资者Kurma Partners、Fountain Healthcare Partners、V-Bio Ventures、Invivo Capital和Omnes Capital也参与其中。Corteria Pharmaceuticals于2021年由Philip Janiak博士和Marie-Laure Ozoux博士共同创立，致力于开发治疗心力衰竭的潜在“first-in-class”药物。Corteria公司的战略是基于人体证据和对患者疾病生物学的深入了解，对患者进行创新性分层和靶点选择，重点关注心力衰竭恶化、急性心力衰竭和右心衰竭。此次融资所得将用于推动公司的心力衰竭产品管线进入临床。#   Garuda Therapeutics完成6200万美元B轮融资Garuda Therapeutics完成6200万美元B轮融资，本轮融资由Northpond Ventures、奥博资本、Cormorant Asset Management和Aisling Capital领投。融资资金将用于支持该公司科技平台的持续开发，以开发现货型、具持续性、以血液干细胞为基础的疗法。Garuda公司的现货型、自我更新的造血干细胞平台，旨在为患者快速提供细胞特征一致、人类白细胞抗原（HLA）匹配的无转基因造血干细胞疗法。根据Garuda公司新闻稿，该公司科学创始人的研究能够将血液中的成熟干细胞转化成为能够自我更新的多能干细胞，这一技术有望克服当前实践的许多局限性。#   益杰立科完成3200万美元A轮融资2023年8月30日消息，益杰立科完成3200万美元A轮融资，由启明创投和奥博资本共同领投，原有投资方晨兴创投参与。本轮资金将用于该公司两个领先项目的临床前开发和早期临床验证，同时还将持续投入未来管线的研发，扩大领导团队建设，并对该公司已建立的核心技术平台持续投入。益杰立科成立于2021年，位于上海，致力于通过表观遗传调控治疗多种疾病，开发下一代基因编辑疗法。据益杰立科新闻稿介绍，其EPIREG技术平台通过人工智能（AI）算法不断探索以获得更优的CRISPR-Cas组件，在不改变DNA序列的情况下，调控目的基因或同时操控多个基因的表达。在同类技术中，该技术平台不需要切割DNA，因此能避免由此带来的潜在风险，如脱靶效应、半衰期短和患者依从性差等问题。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

PARIS, France I September 07, 2023 I Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M [1] ) Series A co-led by US investment firm OrbiMed and EU-based leading investment firm Jeito Capital, with the participation of all existing seed investors (Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, Omnes Capital). As a result, Erez Chimovits from OrbiMed and Andreas Wallnoefer from Jeito Capital will join the board of Directors of Corteria. The funding will be used to advance Corteria’s cardiovascular pipeline into the clinic. Heart failure is a serious disease with a prevalence of more than 60 million patients globally and still growing. Corteria’s innovative approach is centered on selecting therapeutic targets involved in the worsening and acute forms of human heart failure, as well as a stratification strategy to identify specific subgroups that are most likely to benefit from the treatments. These forms of heart failure are widespread, life-threatening, and not directly addressed by the current standards of care. Corteria was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak, and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi, around two cardiovascular programs in-licensed from Sanofi. [2] Since then, Corteria’s pipeline has expanded rapidly and comprises today three first-in-class therapies that are highly differentiated as they produce multi-organ benefits, acting on the kidneys, the heart, and the vessels: The lead asset for Worsening Heart Failure is expected to enter the clinic in early 2024. “This financing marks a major milestone in our mission to bring therapies to heart failure subpopulations with high unmet needs,” said Philip Janiak, Founder and President of Corteria Pharmaceuticals. “ We are extremely grateful to Jeito and OrbiMed as our new investors for their trust in our science and team and to our existing investors for their support and commitment since inception. We are looking forward to working all together to develop next generation transformative therapeutics.” Andreas Wallnoefer, Partner at Jeito Capital, said: “Despite current treatments, heart failure is a progressing disease that impacts severely the lives of many patients and remains one of the leading causes of mortality worldwide. Corteria focuses on translating important therapeutic innovation in cardiology into clinical practice. Our investment in Corteria reflects Jeito’s commitment to address significant unmet needs in the realm of cardiology. We are excited to join forces with Corteria’s dedicated team to develop a portfolio of medicines with important clinical benefit for patients.” “We are proud to have been involved with Corteria since its early days and impressed with the progress made to date. The company is now at a turning point of entering the clinic with its lead asset early next year and validating its unique positioning in well-defined heart failure subpopulations with high unmet medical needs. Kurma Partners is pleased to continue supporting the company during this key step that we hope will bring transformative clinical outcome for patients,” said Thierry Laugel, Managing Partner at Kurma Partners, and Chairman of the board of Corteria. About OrbiMed OrbiMed is a healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. www.orbimed.com About Jeito Capital Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life or follow @Jeito_life on Twitter or LinkedIn . About Corteria Pharmaceuticals Founded in 2021, Corteria Pharmaceuticals is a privately held biopharmaceutical company developing first-in-class drugs in heart failure subpopulations. Despite some improvements in the management of this serious disease, the prevalence of heart failure keeps increasing with more than 60 million patients worldwide. Corteria’s strategy involves innovative patient stratification and target selection based on human evidence and a better understanding of disease biology in patients with a focus on worsening and acute heart failure and right heart failure. More information available at: www.corteriapharma.com [1] Applying a 1.0886 EUR/USD exchange rate as of 30 August 2023 (Banque de France) rounded to $71M [2] CRF2 peptide agonist and AVP neutralizing monoclonal antibody programs [3] Corticotropin-releasing hormone receptor 2 SOURCE: Corteria Pharmaceuticals